Web Exclusives

Papillary thyroid cancer is the most prevalent thyroid cancer, accounting for 80% of thyroid cancer diagnoses. Prognosis is good for patients with early and aggressive treatment, and the new and emerging therapies targeting the RET pathway may improve outcomes for patients with advanced disease. Read More ›

Among patients with radioiodine-refractory advanced or metastatic thyroid cancer, tyrosine kinase inhibitors are guideline recommended. New RET-specific kinase inhibitors have recently demonstrated positive outcomes for these patients. Read More ›

In response to the COVID-19 pandemic, CMS has added coverage of telehealth services as part of a push by the agency to accelerate the use of telehealth by removing reimbursement barriers. Read More ›

The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum. Read More ›

In the treatment of patients with platinum-sensitive, recurrent ovarian cancer, a lower starting dose of niraparib in patients with a low body weight (77 kg) or low platelet count (150,000/μL) had similar efficacy as the fixed 300-mg starting dose versus placebo on the end point of progression-free survival, confirming a previous observation. Read More ›

A review of the National Cancer Database reveals that use of neoadjuvant chemotherapy for advanced epithelial ovarian cancer increased markedly between 2004 and 2016. At the same time, median survival improved by more than 6 months. Study authors found no association between the 2 trends. Read More ›

Data from a real-world setting show that a platinum-free interval >12 months was associated with the best outcomes after progression on PARP inhibitor maintenance in patients with high-grade serous ovarian cancer. Read More ›

On September 4, 2020, the FDA accelerated the approval of pralsetinib (Gavreto; Blueprint Medicines/Genentech), an oral RET inhibitor, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and RET-activating fusions, as detected by an FDA-approved test. Read More ›

Adding abemaciclib to endocrine therapy led to a significant reduction in invasive disease recurrence versus endocrine therapy alone in HR-positive, HER2-negative early-stage breast cancer, according to the results of a new study. “This is a very important trial, and the findings will change practice,” said Giuseppe Curigliano, MD, PhD. Read More ›

ASCO guidelines cite significant improvement in progression-free survival when PARP inhibitors are used as maintenance therapy or in the setting of recurrent disease in women with advanced ovarian cancer who have responded to platinum-based chemotherapy in the first line. Read More ›